JP2001046488A - Curing agent - Google Patents
Curing agentInfo
- Publication number
- JP2001046488A JP2001046488A JP11225684A JP22568499A JP2001046488A JP 2001046488 A JP2001046488 A JP 2001046488A JP 11225684 A JP11225684 A JP 11225684A JP 22568499 A JP22568499 A JP 22568499A JP 2001046488 A JP2001046488 A JP 2001046488A
- Authority
- JP
- Japan
- Prior art keywords
- ray
- curing agent
- component
- rays
- curing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、例えば、破損した
生体内組織の破損箇所の修復、特に外科的な切開手術を
伴わずに生体深奥部の破損箇所を修復させるために用い
る硬化剤及びその製造に関する。さらに、本発明は、例
えば、破損した構造物（建造物等）の破損箇所の修復、
特に構造物内部の破損箇所を修復させるために用いる硬
化剤及びその製造に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to, for example, a sclerosing agent used for repairing a damaged portion of a damaged tissue in a living body, particularly for repairing a damaged portion deep in a living body without surgical incision. Related to manufacturing. Further, the present invention provides, for example, repair of a damaged portion of a damaged structure (such as a building),
In particular, the present invention relates to a curing agent used for repairing a damaged portion inside a structure and its production.
【０００２】[0002]
【従来の技術】従来は、消化器系の疾患や血管静脈瘤の
破裂のような生体内組織の破損に対しては、開腹手術の
ような外科的方法によって破損部周辺を切開し、器具等
を用いて直接破損部を治療するという、いわゆる侵襲的
な方法による治療が行われていた。2. Description of the Related Art Conventionally, in the case of damage to a tissue in a living body such as a digestive system disease or rupture of a vascular varicose vein, an incision is made around the damaged portion by a surgical method such as laparotomy, and instruments and the like are used. The so-called invasive method of treating the damaged part directly using the method has been used.
【０００３】[0003]
【発明が解決しようとする課題】しかしながら、侵襲的
方法による治療は、手術中の出血等のため生体への負担
が大きく、術後の疼痛や手術痕による精神的な傷も残る
ため、近年では内視鏡を使用した治療等のようないわゆ
る非侵襲的な方法による治療が広がりつつある。However, in the treatment by the invasive method, the burden on the living body is large due to bleeding during the operation, and the postoperative pain and the mental scar due to the surgical scar remain. Treatment by so-called non-invasive methods such as treatment using an endoscope is expanding.
【０００４】また、脳内血管破損等のように、周辺部の
他の組織を傷つけることは許されない部位の破損につい
ては、侵襲的方法による治療では、破損箇所を修復する
こと自体が不可能であった。[0004] In the case of damage to a site that is not allowed to damage other tissues in the periphery, such as damage to a blood vessel in the brain, it is impossible to repair the damaged portion by invasive treatment. there were.
【０００５】さらに、破損箇所が生体の深奥部に位置す
る場合には、侵襲的方法による治療では、破損箇所を露
出させるために切開手術を行う際に周りの重要な組織に
傷をつけてしまう恐れがある。[0005] Further, when the damaged portion is located deep inside the living body, in the treatment by the invasive method, a surrounding important tissue is damaged when performing an incision operation to expose the damaged portion. There is fear.
【０００６】このため、現在では、非侵襲的方法にて治
療できる生体組織の領域を広げるための技術開発が危急
の課題となっている。[0006] For this reason, it is an urgent task at present to develop a technique for expanding a region of a living tissue that can be treated by a non-invasive method.
【０００７】一方、生体組織の破損箇所のみならず、建
造物や機械等のような構造物の内部に生じた破損箇所を
修復する場合にも、構造物を破壊・解体することなく破
損箇所を修復することができれば修復作業の手間やコス
トを削減することができる。On the other hand, when repairing not only a damaged portion of a living tissue but also a damaged portion generated inside a structure such as a building or a machine, the damaged portion can be repaired without destroying or dismantling the structure. If it can be repaired, the labor and cost of the repair work can be reduced.
【０００８】本発明は、以上のような課題に鑑みてなさ
れたものであり、生体内の組織破損、特に切開手術を行
えない部位や生体深奥部にて組織破損が生じた場合に、
切開手術を伴わないで破損箇所を修復することを可能に
するための硬化剤等を提供することを目的とする。さら
に、本発明は、構造物の内部に生じた破損箇所を修復す
る場合にも、構造物を破壊・解体することなく破損箇所
を修復することを可能にするための硬化剤等を提供する
ことを目的とする。SUMMARY OF THE INVENTION The present invention has been made in view of the above-described problems, and is intended for use in the case of tissue damage in a living body, particularly when the tissue is damaged in a part where incision surgery cannot be performed or in a deep part of the living body.
An object of the present invention is to provide a sclerosing agent or the like for enabling a damaged portion to be repaired without incision surgery. Further, the present invention provides a hardening agent or the like for enabling repair of a damaged portion without destroying or dismantling the structure even when repairing a damaged portion generated inside the structure. With the goal.
【０００９】[0009]
【課題を解決するための手段】以上のような課題を解決
するために、本発明は、物質透過力の強いＸ線の照射に
直接的にまたは間接的に感応して硬化する成分を硬化剤
に含ませたことを特徴としている。SUMMARY OF THE INVENTION In order to solve the above problems, the present invention relates to a curing agent which cures directly or indirectly in response to irradiation of X-rays having a strong substance-penetrating power. It is characterized by being included in.
【００１０】具体的には、本発明においては下記の硬化
剤を提供する。Specifically, the present invention provides the following curing agents.
【００１１】（１） 生体組織内の所望の箇所で硬化さ
せる硬化剤であって、Ｘ線照射に感応して硬化するＸ線
硬化性成分を含むことを特徴とする硬化剤。(1) A curing agent for curing a desired portion in a living tissue, the curing agent comprising an X-ray curable component which cures in response to X-ray irradiation.
【００１２】（２） 生体組織内の所望の箇所で硬化さ
せる硬化剤であって、Ｘ線を吸収して蛍光を発するＸ線
用蛍光成分と、このＸ線用蛍光成分から発せられた光に
よって硬化する光硬化性成分と、からなる組成物を含む
ことを特徴とする硬化剤。(2) A curing agent that cures at a desired location in a living tissue, and is composed of an X-ray fluorescent component that absorbs X-rays and emits fluorescence, and light emitted from the X-ray fluorescent component. A curing agent comprising a composition comprising a photocurable component that cures.
【００１３】また、以下のような使用も本発明に含まれ
る使用となる。The following uses are also included in the present invention.
【００１４】（３） Ｘ線照射に感応して硬化するＸ線
硬化性樹脂の生体組織用硬化剤製造のための使用。(3) Use of an X-ray curable resin which cures in response to X-ray irradiation for the production of a hardening agent for living tissue.
【００１５】（４） Ｘ線を吸収して蛍光を発するＸ線
用蛍光成分と、このＸ線用蛍光成分から発せられた光に
よって硬化する光硬化性成分と、を含む組成物の生体組
織用硬化剤製造のための使用。(4) A composition containing a fluorescent component for X-rays that absorbs X-rays to emit fluorescence and a photocurable component that is cured by light emitted from the fluorescent component for X-rays, for a living tissue Use for hardener production.
【００１６】さらに、本発明は、以下のような装置をそ
の基本的な構成とする。Further, the present invention has the following apparatus as its basic configuration.
【００１７】（５） 上記（１）又は（２）記載の硬化
剤を生体内に注入するための注入具と、生体内に注入し
た硬化剤を硬化させるためのＸ線を発するＸ線照射装置
と、を備えることを特徴とする装置。(5) An injector for injecting the curing agent according to the above (1) or (2) into a living body, and an X-ray irradiator for emitting X-rays for curing the curing agent injected into the living body. An apparatus comprising:
【００１８】また、本発明は、以下のようなものも提供
する。The present invention also provides the following.
【００１９】（６） 構造物内の所望の箇所で硬化させ
る硬化剤であって、Ｘ線照射に感応して硬化するＸ線硬
化性成分を含むことを特徴とする硬化剤。(6) A curing agent for curing at a desired location in a structure, comprising an X-ray curable component which cures in response to X-ray irradiation.
【００２０】（７） 構造物内の所望の箇所で硬化させ
る硬化剤であって、Ｘ線を吸収して蛍光を発するＸ線用
蛍光成分と、このＸ線用蛍光成分から発せられた光によ
って硬化する光硬化性成分と、からなる組成物を含むこ
とを特徴とする硬化剤。(7) An X-ray fluorescent component that is a curing agent that cures at a desired location in a structure and absorbs X-rays to emit fluorescence, and a light emitted from the X-ray fluorescent component. A curing agent comprising a composition comprising a photocurable component that cures.
【００２１】（８） Ｘ線照射に感応して硬化するＸ線
硬化性樹脂の構造物用硬化剤製造のための使用。(8) Use of an X-ray curable resin which cures in response to X-ray irradiation for the production of a structural curing agent.
【００２２】（９） Ｘ線を吸収して蛍光を発するＸ線
用蛍光成分と、このＸ線用蛍光成分から発せられた光に
よって硬化する光硬化性成分と、を含む組成物の構造物
用硬化剤製造のための使用。(9) For a structure of a composition comprising a fluorescent component for X-rays that absorbs X-rays and emits fluorescence, and a photocurable component that is cured by light emitted from the fluorescent component for X-rays. Use for hardener production.
【００２３】（１０） 上記（６）又は（７）記載の硬
化剤を構造物内部に注入するための注入具と、構造物内
部に注入した硬化剤を硬化させるためのＸ線を発するＸ
線照射装置と、を備えることを特徴とする装置。(10) An injector for injecting the curing agent according to the above (6) or (7) into the inside of the structure, and an X-ray emitting X-ray for curing the curing agent injected into the inside of the structure.
A line irradiation device.
【００２４】＜用語の定義＞ ［硬化剤］本明細書において、「硬化剤」とは、生体組
織内（又は構造物内）の所望の箇所で硬化させるものの
ことを言う。<Definition of Terms> [Hardener] In the present specification, the "hardener" refers to a material that cures at a desired location in a living tissue (or in a structure).
【００２５】［硬化剤で使用される成分］本明細書にお
いて、「成分」とは、「硬化剤」、「組成物」全体の中
の本発明を実現するために用いられる物質を指す一般的
な概念であり、当該「成分」は純物質を指す場合もあ
り、混合物を指す場合もある。[Components Used in Curing Agent] In the present specification, the term “component” generally refers to a substance used for realizing the present invention in the “curing agent” and the “composition” as a whole. The term “component” may refer to a pure substance or a mixture.
【００２６】ここで、「Ｘ線硬化性成分」は、Ｘ線が照
射されるとそれに感応して硬化する成分のことを言い、
「Ｘ線硬化性成分」の代表的なポリマーとしては、具体
的には、ポリ（メタクリル酸グリシジル−Ｃｏ−アクリ
ル酸エチル）、ポリ（２，３−ジクロロ−１−プロピル
アクリレート）、ポリメタクリル酸メチル、ポリ−α−
クロロアクリル酸トリフルオロエチル、ポリメタクリル
酸１，１−ジメチルテトラフロロプロピル、ポリメタク
リル酸ヘキサフロロブチル、ポリ（メタクリル酸メチル
−Ｃｏ−メタクリル酸）、ポリメタクリル酸トリクロロ
エチル等のようなポリマーを挙げることができる。但
し、本発明においてはＸ線照射に感応して硬化する「Ｘ
線硬化性成分」であれば、上記のポリマー以外のポリマ
ーを用いてもよく、更には、オリゴマーやモノマーを用
いてもよい。Here, the “X-ray curable component” refers to a component which cures in response to X-ray irradiation.
Typical polymers of the “X-ray curable component” include, specifically, poly (glycidyl methacrylate-Co-ethyl acrylate), poly (2,3-dichloro-1-propyl acrylate), and polymethacrylic acid. Methyl, poly-α-
Polymers such as trifluoroethyl chloroacrylate, 1,1-dimethyltetrafluoropropyl polymethacrylate, hexafluorobutyl polymethacrylate, poly (methyl methacrylate-Co-methacrylic acid), and polychlorotriethyl ethyl methacrylate are exemplified. be able to. However, in the present invention, "X" which cures in response to X-ray irradiation
As long as it is a "line-curable component", a polymer other than the above-mentioned polymers may be used, and further, an oligomer or a monomer may be used.
【００２７】また、本発明に係る「Ｘ線硬化性成分」
は、「Ｘ線照射に感応して」硬化する成分であればよい
ので、当該成分が主としてＸ線以外の電磁波により硬化
してしまう場合でも、Ｘ線によっても硬化するものであ
れば、本発明に言う「Ｘ線硬化性成分」に該当する。Further, the "X-ray curable component" according to the present invention.
May be any component that can be cured “in response to X-ray irradiation”, so that the present invention may be applied to a case where the component is cured mainly by an electromagnetic wave other than X-rays, as long as it is also cured by X-rays. "X-ray curable component".
【００２８】「樹脂」とは、一般的にはポリマーのこと
を意味するが、本明細書においては、ポリマーのみなら
ず、所定の「成分」を構成要素とするもの又はそれ自体
であれば、モノマーやオリゴマーであっても「樹脂」と
言う。「Ｘ線硬化性樹脂」とは、「Ｘ線硬化性成分」を
含む組成物のことを指し、「Ｘ線硬化性樹脂」はそれ自
体は公知のものであるが、これを本明細書で言うような
「硬化剤」に適用した例はなく、従って「Ｘ線硬化性樹
脂」を生体組織用（又は構造物用）硬化剤を製造するた
めに使用する行為も本発明に含まれる。The term "resin" generally means a polymer, but in the present specification, not only a polymer but also a component having a predetermined "component" or a component itself. Even a monomer or oligomer is called a “resin”. "X-ray-curable resin" refers to a composition containing "X-ray-curable component", and "X-ray-curable resin" is known per se. There is no example of application to such a “hardening agent”, and thus the act of using “X-ray curable resin” to produce a hardening agent for living tissue (or for a structure) is also included in the present invention.
【００２９】「Ｘ線用蛍光成分」は、Ｘ線が照射される
とそれを吸収して蛍光を発するものであり、「Ｘ線用蛍
光成分」としては、ＣａＷＯ４等のタングステン酸塩系
のものや、ＣａＳｉＯ４等のケイ酸塩系のもの等を用い
ることができる。しかし、Ｘ線を吸収して蛍光を発する
「蛍光成分」であれば、上記以外の塩や他の物質から形
成されたものを用いてもよい。The "X-ray fluorescent component" is intended X-rays to fluoresce by absorbing it when irradiated, as the "fluorescent component for X-rays", the tungstate-based, such as CaWO 4 And silicate-based materials such as CaSiO 4 can be used. However, as long as it is a “fluorescent component” that absorbs X-rays and emits fluorescence, a component formed from a salt or another substance other than the above may be used.
【００３０】「光硬化性成分」は、一般的には、所定波
長の光が照射されるとそれに感応して硬化する成分のこ
とを言うが、本発明では、上記Ｘ線用蛍光成分から発せ
られた光によって硬化する成分のことを「光硬化性成
分」と言う。このような「光硬化性成分」の一例として
は、ポリケイ皮酸ビニルが挙げられるが、これ以外の成
分であっても「Ｘ線用蛍光成分から発せられた光によっ
て硬化する」成分であれば、本発明に言う「光硬化性成
分」に該当する。The “photo-curable component” generally refers to a component which cures in response to irradiation with light of a predetermined wavelength. In the present invention, the light-curable component emits light from the X-ray fluorescent component. A component that is cured by the applied light is referred to as a “photocurable component”. An example of such a “photo-curable component” is polyvinyl cinnamate, but any other component as long as it is “a component that is cured by light emitted from the X-ray fluorescent component” And the "photocurable component" according to the present invention.
【００３１】また、「光硬化性成分」は、「Ｘ線用蛍光
成分から発せられた光によって」硬化する成分であれば
いいので、主として「Ｘ線用蛍光成分から発せられた
光」以外の電磁波により硬化する成分であっても「Ｘ線
用蛍光成分から発せられた光」により硬化するものであ
れば、本発明に言う「光硬化性成分」に該当する。The “photo-curable component” may be any component that is cured by “light emitted from the X-ray fluorescent component”, and thus is mainly other than “light emitted from the X-ray fluorescent component”. Even if the component is cured by an electromagnetic wave, if it can be cured by "light emitted from the X-ray fluorescent component", it corresponds to the "photocurable component" in the present invention.
【００３２】さらに、「Ｘ線用蛍光成分」と「光硬化性
成分」とを含む「組成物」を生体組織用（又は構造物
用）硬化剤を製造するために使用する行為も本発明に含
まれる。なお、本明細書において「組成物」と言うとき
は、「Ｘ線用蛍光成分」と「光硬化性成分」とを含むも
ののことを言う。従って、「組成物」は、「Ｘ線用蛍光
成分」や「光硬化性成分」以外の成分を含むものであっ
ても構わない。Furthermore, the act of using a "composition" containing a "fluorescent component for X-rays" and a "photocurable component" to produce a curing agent for living tissue (or for a structure) is also included in the present invention. included. In this specification, the term "composition" refers to a composition containing "fluorescent component for X-ray" and "photocurable component". Therefore, the “composition” may contain components other than the “X-ray fluorescent component” and the “photocurable component”.
【００３３】[装置]生体組織用硬化剤を生体内に注入す
るための「注入具」とは、血管造影剤注入用の針やカテ
ーテル等のように、生体内に挿入でき、体内の組織表面
や管組織内に薬剤を送り込むことができるような器具を
意味する。なお、以下の「発明の実施の形態」では、硬
化剤を生体内の血管あるいはリンパ管等へ注入し、体液
循環により破損箇所に到達させる場合について説明して
いるが、これに限定されず、硬化剤を破損箇所表面に直
接注入するようにしてもよい。[Apparatus] An "injection device" for injecting a sclerosing agent for a living tissue into a living body is a needle or a catheter for injecting a vascular contrast agent, which can be inserted into the living body and has a tissue surface in the body. Or a device capable of delivering a drug into vascular tissue. In the following “Embodiments of the invention”, a case is described in which a sclerosing agent is injected into a blood vessel or a lymphatic vessel or the like in a living body and reaches a damaged portion by circulating a body fluid, but is not limited thereto. The curing agent may be directly injected into the surface of the damaged part.
【００３４】一方、構造物用硬化剤を構造物内部に注入
するための「注入具」とは、ノズルやホース等のよう
に、構造物の内部に挿入でき、構造物内部に薬剤を送り
込むことができるような器具を意味する。On the other hand, an "injection tool" for injecting a hardening agent for a structure into a structure can be inserted into the inside of a structure, such as a nozzle or a hose, and sends a drug into the structure. Means a device that can
【００３５】硬化剤を硬化させるためのＸ線を発する
「Ｘ線照射装置」としては、Ｘ線を発生して照射しうる
一般的なＸ線照射装置を用いればよい。As the "X-ray irradiator" for emitting X-rays for curing the curing agent, a general X-ray irradiator capable of generating and irradiating X-rays may be used.
【００３６】[0036]
【発明の実施の形態】以下に、本発明に係る硬化剤を用
いて、生体組織の破損箇所を修復する場合について説明
する。DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS A case where a damaged portion of a living tissue is repaired by using a curing agent according to the present invention will be described below.
【００３７】[0037]
【実施の形態１】[硬化剤の生体内への注入]本発明に係
る硬化剤（以下、修復剤と言うことがある）を、注入具
１に充填して、図１に示すように、組織の破損箇所につ
ながる上流の血管あるいはリンパ管等のような管状組織
２へ注入する。こうして注入された修復剤は、体液循環
の流れによって流動して目的の破損箇所３へ到達する。[Embodiment 1] [Injection of a sclerosing agent into a living body] A sclerosing agent according to the present invention (hereinafter sometimes referred to as a repairing agent) is filled in an injecting tool 1 and, as shown in FIG. It is injected into a tubular tissue 2 such as an upstream blood vessel or a lymph vessel leading to a tissue break. The restoration agent thus injected flows by the flow of the body fluid circulation and reaches the target breakage point 3.
【００３８】[Ｘ線照射による修復剤の硬化]破損箇所３
に到達した修復剤は、体液（血液またはリンパ液）とと
もにこの破損箇所から組織の外部へと漏出する（図２参
照）。ここで、この漏出した部分の修復剤のみを感応さ
せるために、Ｘ線照射装置２１により、破損箇所の表面
組織部分のみをターゲットとしてＸ線２２を照射する。[Hardening of restoration agent by X-ray irradiation] Damaged part 3
Reaches the tissue from the damaged site together with the body fluid (blood or lymph fluid) (see FIG. 2). Here, in order to sensitize only the repairing agent in the leaked portion, the X-ray irradiator 21 irradiates the X-ray 22 with only the surface tissue portion of the damaged portion as a target.
【００３９】こうすることにより、体内組織の破損箇所
の表面を覆うように修復剤を硬化させることができ、体
外から直接的かつ即効的に破損箇所の修復を実現するこ
とができる。By doing so, the repair agent can be cured so as to cover the surface of the damaged portion of the tissue in the body, and the damaged portion can be repaired directly and immediately from outside the body.
【００４０】[残余薬剤の回収]注入した修復剤のうち表
面で硬化しなかった残余部分については、体液の流れに
よってさらに下流へと流動する。[Recovery of Remaining Drug] The remaining portion of the injected restorative agent that has not been cured on the surface flows further downstream due to the flow of body fluid.
【００４１】ここで、本発明に係る修復剤の組成物が、
生体の代謝機能によって体外へ排泄可能な成分からなる
場合には、未硬化の残余修復材はある程度の時間が経過
した後に体外へ排泄される。Here, the composition of the repairing agent according to the present invention comprises:
In the case of a component that can be excreted outside the body by the metabolic function of the living body, the uncured residual restoration material is excreted outside the body after a certain period of time has elapsed.
【００４２】一方、本発明に係る修復剤の組成物が、生
体の代謝機能によって体外へ排泄されない成分を含む場
合には、再度のＸ線照射によって組織内で硬化するのを
防ぐために、以下のような方策をとる。On the other hand, when the composition of the repairing agent according to the present invention contains a component which is not excreted outside the body due to the metabolic function of the living body, the following composition is used to prevent the composition from being hardened in the tissue by re-irradiation with X-rays. Take such measures.
【００４３】図３に示すように、血管等の破損箇所３の
下流部３１及び上流部３２にバイパスを設けるととも
に、そのバイパスの途中に回収装置４を接合し、体液の
体外循環を確保した上で、本発明に係る修復剤を上流か
ら注入する。As shown in FIG. 3, a bypass is provided in the downstream portion 31 and the upstream portion 32 of the damaged portion 3 such as a blood vessel, and the collecting device 4 is joined in the middle of the bypass to ensure extracorporeal circulation of body fluid. Then, the restoration agent according to the present invention is injected from upstream.
【００４４】こうすることにより、硬化しなかった残余
の修復剤については、下流部３１からのバイパスを経て
回収装置４を通過する際に回収されるので、体内に戻さ
れることがなくなり、体内の未硬化の修復剤を除去する
ことができる。By doing so, the restorative agent that has not hardened is recovered when passing through the recovery device 4 via the bypass from the downstream portion 31, so that it is not returned to the body, and Uncured restorative can be removed.
【００４５】[その他]なお、本発明に係る硬化剤を用い
て生体組織の破損箇所を修復する方法の他の態様として
は、例えば、カテーテル等を用いて破損箇所に硬化剤
を直接送り込み、Ｘ線を照射して被膜を形成する、先
端にマイクロバルーンを取り付けたカテーテルを破損箇
所（例えば動脈瘤）に挿入し、硬化剤を注入してマイク
ロバルーンを膨らませることによって破損箇所を塞ぎ
（動脈瘤の場合には、膨らませたマイクロバルーンで動
脈瘤の空間を埋める）、Ｘ線を照射して硬化剤を硬化さ
せる（マイクロバルーンを用いるのは硬化剤が生体に直
接触れるのを防ぐためであり、このようにすれば安全性
を向上させることができる）、というようなものが考え
られる。[Others] As another embodiment of the method for repairing a damaged portion of a living tissue using the curing agent according to the present invention, for example, the curing agent is directly sent to the damaged portion using a catheter or the like, and X A catheter with a microballoon attached to the tip, which forms a coating by irradiating a ray, is inserted into a damaged site (for example, an aneurysm), and a sclerosing agent is injected to inflate the microballoon to close the damaged site (aneurysm). In the case of, the space of the aneurysm is filled with the inflated micro balloon, and the curing agent is cured by irradiating X-rays (the use of the micro balloon is to prevent the curing agent from directly contacting the living body, In this way, safety can be improved).
【００４６】[0046]
【実施の形態２】本発明に係る硬化剤を用いると建造物
や機械等のような構造物の破損箇所を修復することがで
きる。この場合においては、図４〜図６に示すように、
ノズルやホース等のような注入具７を用いて破損箇所６
に硬化剤を送り込み、Ｘ線を照射して硬化剤を硬化させ
ればよい（なお、図４〜図６において符号５は配管を示
す）。本発明ではＸ線により硬化剤を硬化させているの
で、構造物が光を透過しない不透明な構造物であって
も、構造物を破壊・解体することなく内部の破損箇所を
修復することができる。Embodiment 2 By using the curing agent according to the present invention, it is possible to repair a damaged portion of a structure such as a building or a machine. In this case, as shown in FIGS.
Use an injection tool 7 such as a nozzle or a hose to
A curing agent may be sent to the substrate and X-rays may be applied to cure the curing agent (in FIGS. 4 to 6, reference numeral 5 indicates a pipe). In the present invention, since the curing agent is cured by X-rays, even if the structure is an opaque structure that does not transmit light, it is possible to repair an internal damaged portion without breaking or dismantling the structure. .
【００４７】[0047]
【実施の形態３】また、血液の流れを止める場合（例え
ば、癌細胞に血液を供給する血管を塞ぐことにより、癌
細胞を壊死させるというような治療方法がある）にも、
必要とする箇所において、基本的には前述と同様の手法
により、本発明に係る硬化剤を硬化させることによって
実現することができる。[Embodiment 3] In addition, when stopping the flow of blood (for example, there is a treatment method such as blocking a blood vessel that supplies blood to cancer cells to necrosis the cancer cells).
It can be realized by curing the curing agent according to the present invention at a necessary place by basically the same method as described above.
【００４８】[0048]
【実施の形態４】さらに、不要配管への水の流入を防ぐ
場合（配管を増設した場合に、使用されないこととなっ
た不要配管に水が溜まったままだとその水が腐敗する等
の不都合があるので、不要配管への水の流入を防ぐ必要
がある）にも、必要とする箇所において、やはり基本的
には前述と同様の手法により、本発明に係る硬化剤を硬
化させることによって実現することができる。[Fourth Embodiment] Further, in the case of preventing the inflow of water into unnecessary pipes (in the case where additional pipes are added, there is a disadvantage that the water is spoiled if water remains in the unnecessary pipes that have become unused. Therefore, it is necessary to prevent water from flowing into unnecessary piping), and at a necessary place, it is also realized by curing the curing agent according to the present invention by basically the same method as described above. be able to.
【００４９】[0049]
【発明の効果】本発明によれば、物質透過力の強いＸ線
を使用しているので、硬化剤を生体内の目的の破損箇所
に到達させた後に硬化させることができ、外科的な切開
手術を行うことなく直接的かつ即効的に破損箇所の修復
を実現することができる。また、切開手術を行えない部
位や生体深奥部にて生じた組織破損についても、周辺組
織を傷つけるのを防ぎながら当該箇所を修復することが
可能となる。According to the present invention, since the X-rays having a strong substance penetrating power are used, the sclerosing agent can be hardened after reaching the target damaged part in the living body, and the surgical incision can be performed. It is possible to directly and quickly repair a damaged portion without performing an operation. In addition, even for a tissue breakage occurring in a part where an incision operation cannot be performed or in a deep part of a living body, it is possible to repair the part while preventing the surrounding tissue from being damaged.
【００５０】さらに、本発明によれば、Ｘ線により硬化
剤を硬化させているので、構造物が光を透過しない不透
明な構造物であっても、構造物を破壊・解体することな
く内部の破損箇所を修復することができる。Further, according to the present invention, since the curing agent is cured by X-rays, even if the structure is an opaque structure that does not transmit light, the inside of the structure is not destroyed or disassembled without breaking. Damaged parts can be repaired.
【図１】本発明の硬化剤を生体組織内に注入する様子を
示す模式図である。FIG. 1 is a schematic diagram showing a state in which a curing agent of the present invention is injected into a living tissue.
【図２】本発明の硬化剤を生体組織内で硬化させる様子
を示す模式図である。FIG. 2 is a schematic view showing a state in which the curing agent of the present invention is cured in a living tissue.
【図３】本発明の硬化剤を生体組織内から抜き取る様子
を示す模式図である。FIG. 3 is a schematic view showing a state in which a curing agent of the present invention is extracted from living tissue.
【図４】本発明の硬化剤を構造物内に注入する様子を示
す模式図である。FIG. 4 is a schematic view showing a state in which the curing agent of the present invention is injected into a structure.
【図５】本発明の硬化剤を構造物内に注入する様子を示
す模式図である。FIG. 5 is a schematic view showing a state in which the curing agent of the present invention is injected into a structure.
【図６】本発明の硬化剤を構造物内で硬化させる様子を
示す模式図である。FIG. 6 is a schematic diagram showing a state in which the curing agent of the present invention is cured in a structure.
１ 注入具 ２ 血管 ３ 体内組織破損箇所 ４ 回収装置 ５ 配管 ６ 破損箇所 ７ 注入具 ２１ Ｘ線照射装置 ２２ Ｘ線 ３１ 下流部 ３２ 上流部 DESCRIPTION OF SYMBOLS 1 Injection tool 2 Blood vessel 3 In-vivo tissue damage location 4 Recovery device 5 Piping 6 Damaged location 7 Injection tool 21 X-ray irradiation device 22 X-ray 31 Downstream portion 32 Upstream portion
Claims (10)
化剤であって、Ｘ線照射に感応して硬化するＸ線硬化性
成分を含むことを特徴とする硬化剤。1. A curing agent which cures at a desired location in a living tissue, comprising an X-ray curable component which cures in response to X-ray irradiation.
化剤であって、Ｘ線を吸収して蛍光を発するＸ線用蛍光
成分と、このＸ線用蛍光成分から発せられた光によって
硬化する光硬化性成分と、からなる組成物を含むことを
特徴とする硬化剤。2. A curing agent for curing a desired portion in a living tissue, wherein the curing agent is an X-ray fluorescent component that absorbs X-rays and emits fluorescence, and is cured by light emitted from the X-ray fluorescent component. And a photocurable component.
樹脂の生体組織用硬化剤製造のための使用。3. Use of an X-ray curable resin which cures in response to X-ray irradiation for the production of a hardening agent for living tissue.
成分と、このＸ線用蛍光成分から発せられた光によって
硬化する光硬化性成分と、を含む組成物の生体組織用硬
化剤製造のための使用。4. A hardening composition for living tissue, comprising a fluorescent component for X-rays that absorbs X-rays to emit fluorescence and a photo-curable component that is hardened by light emitted from the fluorescent component for X-rays. Use for agent manufacture.
注入するための注入具と、生体内に注入した硬化剤を硬
化させるためのＸ線を発するＸ線照射装置と、を備える
ことを特徴とする装置。5. An injecting tool for injecting the curing agent according to claim 1 or 2 into a living body, and an X-ray irradiator for emitting X-rays for curing the curing agent injected into the living body. An apparatus characterized in that:
剤であって、Ｘ線照射に感応して硬化するＸ線硬化性成
分を含むことを特徴とする硬化剤。6. A curing agent that cures at a desired location in a structure, comprising an X-ray curable component that cures in response to X-ray irradiation.
剤であって、Ｘ線を吸収して蛍光を発するＸ線用蛍光成
分と、このＸ線用蛍光成分から発せられた光によって硬
化する光硬化性成分と、からなる組成物を含むことを特
徴とする硬化剤。7. A curing agent for curing at a desired location in a structure, wherein the curing agent is an X-ray fluorescent component that absorbs X-rays and emits fluorescence, and is cured by light emitted from the X-ray fluorescent component. And a photocurable component.
樹脂の構造物用硬化剤製造のための使用。8. Use of an X-ray curable resin which cures in response to X-ray irradiation for the production of a structural curing agent.
成分と、このＸ線用蛍光成分から発せられた光によって
硬化する光硬化性成分と、を含む組成物の構造物用硬化
剤製造のための使用。9. A structural curing of a composition comprising an X-ray fluorescent component that absorbs X-rays to emit fluorescence and a photo-curable component that is cured by light emitted from the X-ray fluorescent component. Use for agent manufacture.
内部に注入するための注入具と、構造物内部に注入した
硬化剤を硬化させるためのＸ線を発するＸ線照射装置
と、を備えることを特徴とする装置。10. An injection tool for injecting the curing agent according to claim 6 or 7 into the inside of the structure, an X-ray irradiation device for emitting X-rays for curing the curing agent injected into the inside of the structure, An apparatus comprising:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11225684A JP2001046488A (en) | 1999-08-09 | 1999-08-09 | Curing agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11225684A JP2001046488A (en) | 1999-08-09 | 1999-08-09 | Curing agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001046488A true JP2001046488A (en) | 2001-02-20 |
Family
ID=16833179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11225684A Withdrawn JP2001046488A (en) | 1999-08-09 | 1999-08-09 | Curing agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001046488A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013082943A (en) * | 2008-03-11 | 2013-05-09 | Immunolight Llc | Plasmonic assisted system and method for interior energy-activation from exterior source |
-
1999
- 1999-08-09 JP JP11225684A patent/JP2001046488A/en not_active Withdrawn
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9630022B2 (en) | 2007-04-08 | 2017-04-25 | Immunolight, Llc. | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
| US9498643B2 (en) | 2007-04-08 | 2016-11-22 | Immunolight, Llc | Systems and methods for interior energy-activation from an exterior source |
| US9682250B2 (en) | 2007-04-08 | 2017-06-20 | Immunolight, Llc | Systems and methods for interior energy-activation from an exterior source |
| US10213763B2 (en) | 2007-04-08 | 2019-02-26 | Immunolight, Llc. | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
| US9005406B2 (en) | 2007-04-08 | 2015-04-14 | Immunolight, Llc | Systems and methods for interior energy-activation from an exterior source |
| US9004131B2 (en) | 2007-04-08 | 2015-04-14 | Duke University | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
| US9174190B2 (en) | 2007-04-08 | 2015-11-03 | Immunolight, Llc | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
| US9278331B2 (en) | 2007-04-08 | 2016-03-08 | Immunolight, Llc | Systems and methods for interior energy-activation from an exterior source |
| US10201796B2 (en) | 2007-04-08 | 2019-02-12 | Immunolight, Llc. | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
| US9579523B2 (en) | 2007-04-08 | 2017-02-28 | Immunolight, Llc | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
| US10029117B2 (en) | 2007-04-08 | 2018-07-24 | Immunolight, Llc | Systems and methods for interior energy-activation from an exterior source |
| CN103120923B (en) * | 2008-03-11 | 2014-10-22 | 免疫之光有限责任公司 | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
| CN103120923A (en) * | 2008-03-11 | 2013-05-29 | 免疫之光有限责任公司 | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
| US11278861B2 (en) | 2008-03-11 | 2022-03-22 | Immunolight, Llc | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
| JP2017136591A (en) * | 2008-03-11 | 2017-08-10 | イミュノライト・エルエルシー | Plasmonic assisted systems and methods for interior energy-activation from exterior radiation source |
| US8927615B2 (en) | 2008-03-11 | 2015-01-06 | Immunolight, Llc | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
| JP2019104012A (en) * | 2008-03-11 | 2019-06-27 | イミュノライト・エルエルシー | Plasmonic assisted systems and methods for interior energy-activation from exterior radiation source |
| US10363541B2 (en) | 2008-03-11 | 2019-07-30 | Immunolight, Llc. | Systems and methods for interior energy-activation from an exterior source |
| US10682624B2 (en) | 2008-03-11 | 2020-06-16 | Immunolight, Llc | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
| US10717062B2 (en) | 2008-03-11 | 2020-07-21 | Immunolight, Llc | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
| US11173467B2 (en) | 2008-03-11 | 2021-11-16 | Immunolight, Llc | Systems and methods for interior energy-activation from an exterior source |
| JP2013082943A (en) * | 2008-03-11 | 2013-05-09 | Immunolight Llc | Plasmonic assisted system and method for interior energy-activation from exterior source |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200352649A1 (en) | Methods for implanting and reversing stimuli-responsive implants | |
| US20150257811A1 (en) | System And method For Providing Targeted Ablation Of Parathyroidal Tissue Through Adjuvant Therapy | |
| JP2008506447A (en) | Material delivery system | |
| JP2014039866A (en) | Light delivery system | |
| US20230310056A1 (en) | Materials and treatments using piezoelectric embolic materials | |
| JP2006271831A (en) | Medical treatment device and its usage | |
| Papatsoris et al. | Intracorporeal laser lithotripsy | |
| Germer et al. | Technology for in situ ablation by laparoscopic and image-guided interstitial laser hyperthermia | |
| BR112018009202B1 (en) | METHOD FOR CONNECTING TWO OBJECTS USING A POLYMER COMPOSITION | |
| JP2001046488A (en) | Curing agent | |
| CN101208127A (en) | Material delivery system | |
| US10945739B2 (en) | Device and method for injection, photoactivation and solidifaction of liquid embolic material in the vascular system or other organic cavities | |
| KR101546153B1 (en) | Squirter using ultraviolet curable polymer for aneurysm | |
| RU2554329C2 (en) | Method of baker's cyst surgery | |
| He et al. | Evaluation of a novel circulation system for ureteroscopic laser lithotripsy in vitro | |
| RU2653639C1 (en) | Method of endovenous laser obliteration of an insufficient great saphenous vein in case of its postthrombophlebitic changes and anatomically complex structure of its entry | |
| RU2319469C1 (en) | Surgical method for treating benign nodular neoplasms in mammary gland with high intensity laser radiation | |
| JP2006055337A (en) | Catheter sheath | |
| US20180353195A1 (en) | Medical devices, kits, and methods for stone extraction | |
| Christens-Barry et al. | Fiberoptic delivery of laser energy to remove occlusions from ventricular shunts: technical report | |
| EP0869828A1 (en) | Hemostasis material and apparatus | |
| KR101207011B1 (en) | Expansible apparatus for medical treatment | |
| US11903909B2 (en) | Combined liposuction method | |
| JP2003010314A (en) | Vascular embolus composition | |
| WO2021066012A1 (en) | Irradiation device and treatment method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20061107 |